Download PDF
1 / Pages

Other users also viewed these articles

Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price Mariángeles González Fernández; Elena Villamañán; Inmaculada Jiménez-Nácher; Francisco Moreno; Chamaida Plasencia; Francisco Gayá; Alicia Herrero; Alejandro Balsa;
Reumatol Clin. 2021;17:335-42
Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis José Rosas; María Martín-López; Teresa Otón; Alejandro Balsa; Jaime Calvo-Alén; Raimon Sanmartí; Jesús Tornero; Loreto Carmona;
Reumatol Clin. 2020;16P2:378-85
Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis José María Álvaro-Gracia Álvaro; Petra Díaz del Campo Fontecha; José Luis Andréu Sánchez; Alejandro Balsa Criado; Rafael Cáliz Cáliz; Isabel Castrejón Fernández; Hèctor Corominas; José A. Gómez Puerta; Sara Manrique Arija; Natalia Mena Vázquez; Ana Ortiz García; Chamaida Plasencia Rodríguez; Lucía Silva Fernández; Jesús Tornero Molina;
Reumatol Clin. 2024;20:423-39